False
July 17, 2026
Experts discuss the capabilities companies need to make drug development faster, more flexible, and more resilient – from integrated development and manufacturing flexibility to digital tools, supply chain strategy, and sharper decision-mak...
13 min read
By Alun Evans, James Strachan
July 15, 2026
In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market
10 min read
By Ying K. Tam, Sean Semple
July 13, 2026
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments
6 min read
July 9, 2026
Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality
11 min read
July 7, 2026
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
5 min read
July 6, 2026
A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models
2 min read
July 3, 2026
From clinical translation and regulatory expectations to manufacturing readiness, capital constraints, and commercial viability, experts identify the pressure points shaping the path from discovery to market
13 min read
By LaToya Montgomery, Anis Larbi
July 2, 2026
How single-cell analysis is evolving to improve vaccine development
4 min read
June 30, 2026
A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice
2 min read
By Laurent Claisse
June 30, 2026
Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes
7 min read
False